Johnson & Johnson sued the U.S. Health and Human Services Department on Tuesday, accusing the agency of blocking its plan to ...

The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.

Johnson & Johnson is challenging a federal health agency for blocking its plan to discount drugs through a rebate model ...

now the second-largest federal drug initiative after Medicare, has been exploited by entities not intended initially as beneficiaries, sidelining patients. In August 2024, Johnson & Johnson proposed a ...

On September 26, 2024, the Centers for Medicare & Medicaid Services (CMS) released a final rule implementing changes to the ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

The antitrust regulator said Wednesday it has imposed fines worth 300 million won (US$213,000) on Jeil Pharmaceutical Co., a ...

Johnson & Johnson files suit against HHS over 340B program, proposing hospitals pay full price upfront for drugs and receive ...

J&J announced its plan to replace upfront 34B discounts with the rebate plan in August, but HRSA told the company on Sept. 27 that it would initiate proceedings to terminate the drug maker's ...

A New York Times report found that pharmacy benefit managers push patients toward medications with higher out-of-pocket costs to increase their own profits. Additionally, PBMs often negotiate ...

“The traditional pharmacy, the dispensing model is not gonna survive,” McDonough said. While pharmacy closures are an obvious challenge to patient access, he says some pharmacies are reducing hours or ...